Brief: Electrocore "Vanquish" Clinical Trial Suggests Safety & Efficacy Of NVNS For Treatment Of Headache Associated With Subarachnoid Hemorrhage
Oct 10 (Reuters) - electroCore, Inc. ECOR.O :
* ELECTROCORE. - "VANQUISH" CLINICAL TRIAL (N=40) SUGGESTS
SAFETY
& EFFICACY OF NVNS FOR TREATMENT OF HEADACHE ASSOCIATED WITH
SUBARACHNOID HEMORRHAGE
* ELECTROCORE - "NOVIS" CLINICAL TRIAL (N=150) OF NVNS FOR
ACUTE
TREATMENT OF ISCHEMIC STROKE WILL COMPLETE RECRUITMENT IN 2023
Source text for Eikon: ID:nGNX29Pf0W
Further company coverage: ECOR.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on electroCore
See all newselectroCore, Inc. reports results for the quarter ended June 30 - Earnings Summary
electroCore Q2 revenue jumps, but slightly misses estimates
Brief: electroCore Q2 Net Income USD -3.059 Million
electroCore, Inc. expected to post a loss of 42 cents a share - Earnings Preview
electroCore reiterates FY 2026 revenue guidance